Vaxxinity Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Vaxxinity ha un patrimonio netto totale di $13.4M e un debito totale di $15.2M, che porta il suo rapporto debito/patrimonio netto a 113.1%. Le sue attività totali e le sue passività totali sono rispettivamente $44.3M e $30.9M.

Informazioni chiave

113.1%

Rapporto debito/patrimonio netto

US$15.17m

Debito

Indice di copertura degli interessi	n/a
Contanti	US$30.64m
Patrimonio netto	US$13.41m
Totale passività	US$30.90m
Totale attività	US$44.31m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

A Look At The Intrinsic Value Of Vaxxinity, Inc. (NASDAQ:VAXX)

Jan 08

Vaxxinity initiates rolling submission for its COVID-19 shot with UK's drug regulator

Sep 12

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $33.2M ) di VAXX superano le sue passività a breve termine ( $17.6M ).

Passività a lungo termine: Le attività a breve termine di VAXX ( $33.2M ) superano le sue passività a lungo termine ( $13.3M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: VAXX ha più liquidità del suo debito totale.

Riduzione del debito: Dati insufficienti per determinare se il rapporto debito/patrimonio netto di VAXX si sia ridotto negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: Dati insufficienti per determinare se VAXX ha una pista di cassa sufficiente in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: Dati insufficienti per determinare se VAXX ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.

Vaxxinity Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Vaxxinity Files Form 15

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

Vaxxinity, Inc. Receives A Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Recent updates

Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine

Vaxxinity Files Form 15

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

Vaxxinity, Inc. Receives A Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Vaxxinity, Inc. Announces the Publication of Data from Multiple Non-Human Primate Studies

Vaxxinity, Inc. to Present Data from UB-312 Program in Parkinson's Disease at International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog Disorders

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Vaxxinity, Inc. Announces Resignation of Katherine Eade from the Board of Directors

New major risk - Financial position

High number of new directors

Vaxxinity, Inc. Announces Executive Changes

Vaxxinity, Inc. Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's Disease

New minor risk - Financial position

Vaxxinity, Inc. Announces Executive Changes

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease

Non-Employee Independent Director exercised options to buy US$1.0m worth of stock.

Less than half of directors are independent

Vaxxinity, Inc. Announces the Relocation of its Corporate Headquarters

A Look At The Intrinsic Value Of Vaxxinity, Inc. (NASDAQ:VAXX)

Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

Price target decreased to US$13.50

Less than half of directors are independent

Price target decreased to US$13.50

Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine

Vaxxinity initiates rolling submission for its COVID-19 shot with UK's drug regulator

Vaxxinity's Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non Human Primates

Vaxxinity, Inc. Presents Preclinical Data on Tau Vaccine Candidates At the 2022 Alzheimer's Association International Conference

Less than half of directors are independent

The Coalition for Epidemic Preparedness Innovations to Co-Fund Vaxxinity, Inc.'s Pivotal Phase 3 UB-612 Heterologous Booster Trial to Combat SARS-CoV-2 variants

Less than half of directors are independent

Vaxxinity, Inc. Announces First Participant Dosed in Phase 3 Study of Next-Generation Covid-19 Vaccine Booster

Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern

Vaxxinity, Inc. Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Non-Employee Independent Director recently bought US$63k worth of stock

Co-Founder & Executive Chairman recently bought US$242k worth of stock

Less than half of directors are independent

Second quarter 2021 earnings released: US$0.39 loss per share

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane